Richard C. Malabre net worth and biography

Richard Malabre Biography and Net Worth

Richard Malabre is the CAO of Akebia Therapeutics. They are 65 years old.

What is Richard C. Malabre's net worth?: The estimated net worth of Richard C. Malabre is at least $425.13 thousand as of February 2nd, 2026. Malabre owns 299,390 shares of Akebia Therapeutics stock worth more than $425,134 as of March 22nd. This net worth evaluation does not reflect any other assets that Malabre may own. Learn More about Richard C. Malabre's net worth.
How old is Richard C. Malabre?: Malabre is currently 63 years old. Learn More on Richard C. Malabre's age.
How do I contact Richard C. Malabre?: The corporate mailing address for Malabre and other Akebia Therapeutics executives is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Akebia Therapeutics can also be reached via phone at (617) 871-2098 and via email at [email protected]. Learn More on Richard C. Malabre's contact information.
Has Richard C. Malabre been buying or selling shares of Akebia Therapeutics?: During the last ninety days, Richard C. Malabre has sold $68,838.36 in Akebia Therapeutics stock. Most recently, Richard C. Malabre sold 49,524 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.39, for a transaction totalling $68,838.36. Following the completion of the sale, the chief accounting officer now directly owns 299,390 shares of the company's stock, valued at $416,152.10. Learn More on Richard C. Malabre's trading history.
Who are Akebia Therapeutics' active insiders?: Akebia Therapeutics' insider roster includes Steven Burke (SVP), John Butler (CEO), Violetta Cotreau (CAO), Michel Dahan (COO), Steven Gilman (Director), Nicholas Grund (Insider), Richard Malabre (CAO), Erik Ostrowski (Senior Vice President, Chief Financial Officer & Chief Business Officer), and David Spellman (CFO). Learn More on Akebia Therapeutics' active insiders.
Are insiders buying or selling shares of Akebia Therapeutics?: During the last twelve months, Akebia Therapeutics insiders bought shares 1 times. They purchased a total of 69,270 shares worth more than $86,587.50. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 119,172 shares worth more than $327,679.76. The most recent insider tranaction occured on March, 4th when CEO John P Butler bought 69,270 shares worth more than $86,587.50. Insiders at Akebia Therapeutics own 3.0% of the company. Learn More about insider trades at Akebia Therapeutics.
Information on this page was last updated on 3/4/2026.

Richard C. Malabre Insider Trading History at Akebia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/2/2026	Sell	49,524	$1.39	$68,838.36	299,390
6/9/2025	Sell	15,000	$4.01	$60,150.00	266,914
6/4/2025	Sell	13,334	$3.53	$47,069.02	266,914
2/3/2025	Sell	30,202	$2.10	$63,424.20	280,248

Richard C. Malabre Buying and Selling Activity at Akebia Therapeutics

Akebia Therapeutics Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.42

$1.39

$1.46

50 Day Range

MA: $1.35

$1.18

$1.55

2 Week Range

Now: $1.42

$1.14

$4.08

Volume

7,622,054 shs

Average Volume

3,085,911 shs

Market Capitalization

$380.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Richard Malabre Biography and Net Worth

What is Richard C. Malabre's net worth?

How old is Richard C. Malabre?

How do I contact Richard C. Malabre?

Has Richard C. Malabre been buying or selling shares of Akebia Therapeutics?

Who are Akebia Therapeutics' active insiders?

Are insiders buying or selling shares of Akebia Therapeutics?